0001104659-22-025148.txt : 20220218 0001104659-22-025148.hdr.sgml : 20220218 20220218160559 ACCESSION NUMBER: 0001104659-22-025148 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220216 FILED AS OF DATE: 20220218 DATE AS OF CHANGE: 20220218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dierks Jeffrey CENTRAL INDEX KEY: 0001821102 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 22652688 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 tm227120-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-02-16 0 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001821102 Dierks Jeffrey 630 W. GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 0 1 0 0 Chief Commercial Officer Common Stock 2022-02-16 4 M 0 4259 24.00 A 4259 D Common Stock 2022-02-16 4 S 0 4259 40.0542 D 0 D Common Stock 2022-02-17 4 M 0 200 24.00 A 200 D Common Stock 2022-02-17 4 S 0 4259 40.015 D 0 D Stock Option 24.00 2022-02-16 4 M 0 4259 0 D 2030-08-18 Common Stock 4259 140597 D Stock Option 24.00 2022-02-17 4 M 0 200 0 D 2030-08-18 Common Stock 200 140397 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests in five equal annual installments beginning on August 21, 2021. /s/ Christian Ulrich, Attorney-in-fact for Jeffrey Dierks 2022-02-18